Chlorophacinone

Last updated
Chlorophacinone
Chlorophacinone.svg
Names
Preferred IUPAC name
2-[(4-Chlorophenyl)phenylacetyl]-1H-indene-1,3(2H)-dione
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.020.912 OOjs UI icon edit-ltr-progressive.svg
KEGG
PubChem CID
UNII
  • InChI=1S/C23H15ClO3/c24-16-12-10-15(11-13-16)19(14-6-2-1-3-7-14)23(27)20-21(25)17-8-4-5-9-18(17)22(20)26/h1-13,19-20H Yes check.svgY
    Key: UDHXJZHVNHGCEC-UHFFFAOYSA-N Yes check.svgY
  • InChI=1/C23H15ClO3/c24-16-12-10-15(11-13-16)19(14-6-2-1-3-7-14)23(27)20-21(25)17-8-4-5-9-18(17)22(20)26/h1-13,19-20H
    Key: UDHXJZHVNHGCEC-UHFFFAOYAM
  • Clc1ccc(cc1)C(c2ccccc2)C(=O)C4C(=O)c3ccccc3C4=O
Properties
C23H15ClO3
Molar mass 374.82 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Chlorophacinone is a first-generation anticoagulant rodenticide. The mechanism of action results in internal bleeding due to non-functional clotting factors. It was used as a toxin to control rodent populations. It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002) and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities. [1]

Contents

History

The French company Liphatech (formerly known as Lipha), which had previous experience with creating anticoagulants for the treatment of heart patients, created chlorophacinone in 1961 and branded it “Rozol”. Chlorophacinone belongs to the first-generation anticoagulant rodenticide group, first being developed during the 1940s to 1960s to control rodents in terrestrial environments. [2] [3] [4] Its use began being replaced during the 1970s, along with the use of other rodenticides of its group, by the more potent second-generation anticoagulant rodenticides, when several studies provided information which depicted a developed resistance of rodents to Warfarin (another first-generation anticoagulant rodenticide) in northern Europe and the United States along with a discovered cross-resistance to all first-generation anticoagulant rodenticides. This was found to be caused by a single, dominant and autosomal gene which raised the rodent's dietary requirement for vitamin K (the vitamin whose production anticoagulants primarily inhibited) to twenty times the normal amount. [5] Even though its use has diminished, chlorophacinone can still be bought for rodenticide use, for situations in which conventional bait for rodenticidal purposes cannot be used. [6]

Structure and physical properties

Chlorophacinone is an organic compound with the following systematic name: (2-[2-(4-chlorophenyl)-2-phenylacetyl]indan-1,3-dione. The structure consists of an acetyl group, connected on one side to indanedione ring. Two phenyl groups are attached to the other side, one contains a chloride. Chlorophacinone contains one optically active carbon and therefore it occurs as two enantiomers.

Henry's law constant of 5.12 x 10−7 atm-m3/mol suggests a low potential to volatilize from water or soil into the atmosphere. It is dissolves relatively good in organic solvents like hexane (854 mg/L at 25 °C) and methanol (786 mg/L at 25 °C), compared to water (3.43 mg/L at 25 °C). [4] [7]

AppearancePale-yellow powder
Melting point143.0 °C
Hazard statementsH360D: May damage the unborn child

H300: Fatal if swallowed

H310: Fatal in contact with skin

H330: Fatal if inhaled

H372: Causes damage to the blood through prolonged or

repeated exposure

H410: Very toxic to aquatic life with long lasting effects

Relative density1.4301 g/mL
Vapour pressure4.76 x 10−4 Pa at 23 °C
Henry's law constant5.12 x 10−7 atm-m3/mol
UV/Vis absorption~260 nm and 315 nm

Synthesis

Figure 1: the synthesis of Chlorophacinone. a) SnCl4, 70degC, 8 h, 85% ; b) 25degC, 12 h, quant, ; c) AlCl3, 25degC, 12h, 60% Synthesis chlorophacinone.png
Figure 1: the synthesis of Chlorophacinone. a) SnCl4, 70°C, 8 h, 85% ; b) 25°C, 12 h, quant, ; c) AlCl3, 25°C, 12h, 60%

Chlorophacinone can be synthesized through different mechanisms. A more recently studied mechanism will be discussed below (figure 1). In this synthesizes chlorophacinone is synthesized with less production of side products compared to the classic mechanisms.

The synthesis uses mandelic acid 1 as starting product as it is a cheap and commercially available. Mandelic acid reacts with chlorobenzene 2 in presence of SnCl4 to afford 85% of the phenylacetic acid 3. Thereafter, the phenylacetic acid is treated with oxalyl chloride at room temperature to obtain 6-chloro-2,2-diphenylacetyl chloride 4. No purification is needed to start the last step of the synthesis, which is a Friedel-Crafts reaction of the previously obtained compound 4 with 1,3- indanedione 5. This reaction provided the final product, chlorophacinone 6, with no significant amount of diphacinone or other side products. [8]

Mechanism of action

Figure 2: The vitamin K redox cycle and the inhibition of chlorophacinone of VKOR. Vitamink cycle.png
Figure 2: The vitamin K redox cycle and the inhibition of chlorophacinone of VKOR.

Chlorophacinone is a first-generation anticoagulant rodenticide. The compound is an indandione derivate. It acts as a vitamin K antagonist and exerts its anticoagulatory effect by interfering with the hepatic synthesis of vitamin K-dependent clotting factors. [4] Synthesis of clotting factor II, VII, IX and X involves the posttranslational carboxylation of glutamate to γ-carboxyglutamate by the enzyme γ-glutamyl carboxylase (GGCX). The γ-carboxyglutamate residues promote the binding of clotting factors to phospholipids of the blood vessels, thereby accelerating coagulation. However, a vitamin K hydroquinone (KH2) cofactor is needed for the carboxylation reaction to occur. The KH2 is converted to vitamin K 2,3 epoxide (KO) during the carboxylation reaction. The KH2 cofactor is created within the vitamin K redox cycle. Chlorophacinone interferes with the vitamin K redox cycle by inhibiting vitamin K epoxide reductase (VKOR), an integral membrane protein present in the endoplasmic reticulum (ER). The enzyme plays a vital role within this cycle. The catalytic activity of VKOR is required for the reduction of KO to vitamin K to KH2. The inhibition of VKOR by chlorophacinone prevents the recycling of vitamin K from KO to KH2 (figure 2). Therefore, the supply of KH2 in the tissue will diminish, this in turn will decrease the carboxylation activity of γ-glutamyl carboxylase. [9] [10] Resulting in under-carboxylation of clotting factors, meaning they are no longer capable of binding to the endothelial surface of blood vessels, and thus are biologically inactive. [11]

Metabolism

The chlorophacinone is absorbed through the gastrointestinal tract and may also be absorbed through the skin and respiratory system. [12] When orally ingested absorption of chlorophacinone peaks between 4 and 6 hours after initial ingesting. The compound has a half-life of approximately 10 hours. Highest concentrations of chlorophacinone are found in the liver and kidneys. Repeated oral dosing in rats suggests bioaccumulation in the liver. [4] After 1–4 days of repeated exposure a steady-state phase is reached. The time it takes to reach a steady-state phase suggest rapid elimination of chlorophacinone from the body. [7] Anticoagulants are rapidly and principally absorbed in the intestine. The rodenticide was found to metabolized in the liver. Metabolism is mediated by cytochrome P450 isozymes and ring hydroxylation also appears to be an important biotransformation step. Hydroxylation occurs on the phenyl and indandionyl rings, [13] these metabolites can then further undergo conjugation with glucuronic acid prior to entering the systemic circulation, with potential enterohepatic recirculation. Hepatic metabolism is generally biphasic with a rapid initial phase and more prolonged terminal phase. [9] However metabolite excretion pathways of chlorophacinone still remain poorly described. The major route of elimination of chlorophacinone is through the feces (~95%) however with minor excretion (<1%) through urine and respiration. 26% of chlorophacinone is excreted within eight hours post-exposure via the bile. [4]

Efficacy

Chlorophacinone is used as an anticoagulant rodenticide to control rodent populations in terrestrial environments. It has been proven to be very effective in efficacy studies in rats, mice and beavers. [14] [15] Out of the four toxicants strychnine, zinc phosphide, chlorophacinone and diphacinone, the efficacy of chlorophacinone has been proven to be the highest in controlling mountain beaver populations. Chronic ingestion of smaller doses over time proves to be more toxic than acute ingestion of the same dose, a common trait among anticoagulant rodenticides. [16]

Effects on animals

Belonging to the group of first-generation anticoagulant rodenticides, chlorophacinone has similar symptoms on animals as the other chemicals in its category. Specifically, after being ingested several times by the target animal (most often a rodent), it interferes with the clotting of the blood and leads to internal bleeding, eventually causing death within 5 to 7 days. This effect is due to the rodenticide's inhibition of the vitamin K(1)-2,3 epoxide reductase (VKOR) enzyme which is responsible for the synthesis of vitamin K and therefore the clotting factors II, VII, IX and X, factors critical to blood clotting, lack of which eventually causes mass hemorrhage inside the animal. Although internal bleeding is the usual cause of death in this category of rodenticides, chlorophacinone has also been shown to cause additional cardiopulmonary or neurologic symptoms in laboratory rats, often leading to their death before significant bleeding occurs. [5] [17]

Toxicity

Chlorophacinone is classified as a highly toxic substance when administered orally, dermally, or through inhalation in mammals, falling under Toxicity Category I. It is not a dermal or eye irritant, or a dermal sensitizer (Toxicity Category IV). [4] Accidental exposure incidents involving lambs have shown symptoms including epistaxis, respiratory distress, and facial and cervical swelling. Post-mortem examination in two of the affected lambs have revealed that all organs had a pale appearance, notably the liver, and that the lungs were heavier than usual and were slightly brownish. [18] In four beavers exposed to 2.13 ± 0.4 mg/kg chlorophacinone, bleeding from the mouth, gasping for breath and convulsions were observed, and the beavers died within 15 days after exposure. [16] Studies in rats have indicated that male rats experience more profound effects than female rats. Birds are not as sensitive to chlorophacinone as mammals, but they may still experience sublethal effects from it, such as external bleeding, internal hematoma and increased blood coagulation time. General toxic symptoms include dyspnea, lethargy, hemorrhage from the nose and urethral bleeding. [4]

The LD50 values for different species:

SpeciesLD50 value (mg/kg)
Male rat3.15
Female rat10.95
Rabbit0.329
Black-tailed prairie dog1.94
Northern bobwhite258
Redworm>300

The SENSOR-pesticide database documented 12 human exposure cases involving chlorophacinone between 1998 and 2011. One was a moderate severity case, which involved an insulation worker being exposed to chlorophacinone dust by touching and/or inhaling it. The worker experienced shakiness, fever, and vomiting, as well as respiratory, neurological, gastrointestinal, renal and cardiovascular symptoms. Another case involved a homeowner who experienced shortness of breath and coughing after accidentally inhaling chlorophacinone. No carcinogenicity assessments have been conducted on chlorophacinone since chronic exposure is not likely to occur. [4]

Environmental risk

In order to control the population of animals such as prairie dogs, pocket gophers, mountain beavers and ground squirrels, chlorophacinone bait is distributed into burrow openings or on the ground just outside burrows. Although each placement is covered with grass or shingle to avoid exposing nontarget organisms and chlorophacinone is not likely to drain into soil, nontarget organisms could still be exposed to chlorophacinone by eating the bait. Predators could also eat animals poisoned with chlorophacinone, which is classified as secondary exposure, although multiple poisoned animals must be consumed to receive a lethal dose. The anticoagulant concentration is diluted ten-fold in secondary exposure, and even more when the predator also eats non-poisoned prey. [16] Small, granivorous animals that share burrows with the target animal are mainly at risk to be exposed. In a study summarized by USEPA (2004), chlorophacinone baits were used to control California ground squirrels in rangelands, and nontarget deer mice and San Joaquin pocket mice were found dead with at least 86% of the mortalities likely due to bait exposure. The risk of chlorophacinone exposure to birds is minimal, and the aquatic and terrestrial plant exposure is considered negligible. [4]

See also

Related Research Articles

<span class="mw-page-title-main">Vitamin K</span> Fat-soluble vitamers

Vitamin K is a family of structurally similar, fat-soluble vitamers found in foods and marketed as dietary supplements. The human body requires vitamin K for post-synthesis modification of certain proteins that are required for blood coagulation or for controlling binding of calcium in bones and other tissues. The complete synthesis involves final modification of these so-called "Gla proteins" by the enzyme gamma-glutamyl carboxylase that uses vitamin K as a cofactor.

<span class="mw-page-title-main">Warfarin</span> Medication

Warfarin is an anticoagulant used as a medication under several brand names including Coumadin. While the drug is described as a "blood thinner", it does not reduce viscosity but rather inhibits coagulation. Accordingly, it is commonly used to prevent blood clots in the circulatory system such as deep vein thrombosis and pulmonary embolism, and to protect against stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Less commonly, it is used following ST-segment elevation myocardial infarction and orthopedic surgery. It is usually taken by mouth, but may also be administered intravenously.

<span class="mw-page-title-main">Cholecalciferol</span> Vitamin D3, a chemical compound

Cholecalciferol, also known as vitamin D3 and colecalciferol, is a type of vitamin D that is made by the skin when exposed to sunlight; it is found in some foods and can be taken as a dietary supplement.

<span class="mw-page-title-main">Carboxyglutamic acid</span> Chemical compound

Carboxyglutamic acid, is an uncommon amino acid introduced into proteins by a post-translational carboxylation of glutamic acid residues. This modification is found, for example, in clotting factors and other proteins of the coagulation cascade. This modification introduces an affinity for calcium ions. In the blood coagulation cascade, vitamin K is required to introduce γ-carboxylation of clotting factors II, VII, IX, X and protein Z.

<span class="mw-page-title-main">Rodenticide</span> Chemical used to kill rodents

Rodenticides are chemicals made and sold for the purpose of killing rodents. While commonly referred to as "rat poison", rodenticides are also used to kill mice, woodchucks, chipmunks, porcupines, nutria, beavers, and voles. Despite the crucial roles that rodents play in nature, there are times when they need to be controlled.

<span class="mw-page-title-main">Bromethalin</span> Chemical compound

Bromethalin is a neurotoxic rodenticide that damages the central nervous system.

<span class="mw-page-title-main">Vitamin D toxicity</span> Human disease

Vitamin D toxicity, or hypervitaminosis D is the toxic state of an excess of vitamin D. The normal range for blood concentration in adults is 20 to 50 nanograms per milliliter (ng/mL).

<span class="mw-page-title-main">Hypoprothrombinemia</span> Medical condition

Hypoprothrombinemia is a rare blood disorder in which a deficiency in immunoreactive prothrombin, produced in the liver, results in an impaired blood clotting reaction, leading to an increased physiological risk for spontaneous bleeding. This condition can be observed in the gastrointestinal system, cranial vault, and superficial integumentary system, affecting both the male and female population. Prothrombin is a critical protein that is involved in the process of hemostasis, as well as illustrating procoagulant activities. This condition is characterized as an autosomal recessive inheritance congenital coagulation disorder affecting 1 per 2,000,000 of the population, worldwide, but is also attributed as acquired.

<span class="mw-page-title-main">Fetal warfarin syndrome</span> Congenital disorder caused by maternal warfarin administration

Fetal warfarin syndrome is a disorder of the embryo which occurs in a child whose mother took the medication warfarin during pregnancy. Resulting abnormalities include low birth weight, slower growth, intellectual disability, deafness, small head size, and malformed bones, cartilage, and joints.

<span class="mw-page-title-main">Coumatetralyl</span> Chemical compound

Coumatetralyl is an anticoagulant of the 4-hydroxycoumarin vitamin K antagonist type used as a rodenticide.

<span class="mw-page-title-main">Phenprocoumon</span> Drug

Phenprocoumon is a long-acting blood thinner drug to be taken by mouth, and a coumarin derivative. It acts as a vitamin K antagonist and inhibits blood clotting (coagulation) by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders such as heart attacks and pulmonary (lung) embolism. The most common adverse effect is bleeding. The drug interacts with a large number of other medications, including aspirin and St John's Wort. It is the standard coumarin used in Germany, Austria, and other European countries.

<span class="mw-page-title-main">4-Hydroxycoumarins</span>

4-Hydroxycoumarins are a class of vitamin K antagonist (VKA) anticoagulant drug molecules derived from coumarin by adding a hydroxy group at the 4 position to obtain 4-hydroxycoumarin, then adding a large aromatic substituent at the 3-position. The large 3-position substituent is required for anticoagulant activity.

<span class="mw-page-title-main">Vitamin K epoxide reductase</span> Class of enzymes

Vitamin K epoxide reductase (VKOR) is an enzyme that reduces vitamin K after it has been oxidised in the carboxylation of glutamic acid residues in blood coagulation enzymes. VKOR is a member of a large family of predicted enzymes that are present in vertebrates, Drosophila, plants, bacteria and archaea. In some plant and bacterial homologues, the VKOR domain is fused with domains of the thioredoxin family of oxidoreductases.

<span class="mw-page-title-main">Brodifacoum</span> Chemical compound

Brodifacoum is a highly lethal 4-hydroxycoumarin vitamin K antagonist anticoagulant poison. In recent years, it has become one of the world's most widely used pesticides. It is typically used as a rodenticide, but is also used to control larger pests such as possums.

<span class="mw-page-title-main">Diphenadione</span> Chemical compound

Diphenadione is a vitamin K antagonist that has anticoagulant effects and is used as a rodenticide against rats, mice, voles, ground squirrels and other rodents. The chemical compound is an anti-coagulant with active half-life longer than warfarin and other synthetic 1,3-indandione anticoagulants.

<span class="mw-page-title-main">Bromadiolone</span> Chemical compound

Bromadiolone is a potent anticoagulant rodenticide. It is a second-generation 4-hydroxycoumarin derivative and vitamin K antagonist, often called a "super-warfarin" for its added potency and tendency to accumulate in the liver of the poisoned organism. When first introduced to the UK market in 1980, it was effective against rodent populations that had become resistant to first generation anticoagulants.

<span class="mw-page-title-main">VKORC1</span> Protein-coding gene in the species Homo sapiens

The human gene VKORC1 encodes for the enzyme, Vitamin K epOxide Reductase Complex (VKORC) subunit 1. This enzymatic protein complex is responsible for reducing vitamin K 2,3-epoxide to its active form, which is important for effective clotting (coagulation). In humans, mutations in this gene can be associated with deficiencies in vitamin-K-dependent clotting factors.

<span class="mw-page-title-main">Difenacoum</span> Chemical compound

Difenacoum is an anticoagulant of the 4-hydroxycoumarin vitamin K antagonist type. It has anticoagulant effects and is used commercially as a rodenticide. It was first introduced in 1976 and first registered in the USA in 2007.

<span class="mw-page-title-main">Vitamin K antagonist</span>

Vitamin K antagonists (VKA) are a group of substances that reduce blood clotting by reducing the action of vitamin K. The term "vitamin K antagonist" is technically a misnomer, as the drugs do not directly antagonize the action of vitamin K in the pharmacological sense, but rather the recycling of vitamin K. Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for more than 50 years.

d-CON American brand of rodent control products

d-CON is a brand of rodent control products, which is distributed and owned in the United States by the UK-based consumer goods company Reckitt.

References

  1. ↑ "40 C.F.R.: Appendix A to Part 355—The List of Extremely Hazardous Substances and Their Threshold Planning Quantities" (PDF) (July 1, 2008 ed.). Government Printing Office . Retrieved October 29, 2011.{{cite journal}}: Cite journal requires |journal= (help)
  2. ↑ "Rodenticides: Background & Hazards | Safe Rodent Control" . Retrieved 2024-03-14.
  3. ↑ "History". liphatech.com. Retrieved 2024-03-14.
  4. 1 2 3 4 5 6 7 8 9 Lemay A, McCaskill M, Warren J, Hall, T.C, Paz L, Deliberto S, Ruell E, Wimberly (March 2023). "The use of chlorophacinone in Wildlife damage management" (PDF).{{cite web}}: CS1 maint: multiple names: authors list (link)
  5. 1 2 Hadler M, Buckle A (1992). "Forty Five Years of Anticoagulant Rodenticides - Past, Present and Future Trends" (PDF). p. 36.
  6. ↑ "Rozol Tracking Powder". liphatech.com. Retrieved 2024-03-14.
  7. 1 2 "Evaluation of active substances; Renewal of approval; Assessment Report; Chlorophacinone". July 2016.
  8. ↑ Csuk, René; Barthel, Alexander; Ströhl, Dieter (2011-01-01). "An Alternative and Efficient Route to Chlorophacinone". Zeitschrift für Naturforschung B. 66 (1): 95–97. doi: 10.1515/znb-2011-0116 . ISSN   1865-7117.
  9. 1 2 Van den Brink NW, Elliott JE, Shore RF, Rattner BA. (2017). Anticoagulant Rodenticides and Wildlife. Springer. pp. 87–108.{{cite book}}: CS1 maint: multiple names: authors list (link)
  10. ↑ Tie, Jian-Ke; Stafford, Darrel W. (2008), "Structure and Function of Vitamin K Epoxide Reductase", Vitamins & Hormones, 78, Elsevier: 103–130, doi:10.1016/s0083-6729(07)00006-4, ISBN   978-0-12-374113-4, PMID   18374192 , retrieved 2024-03-14
  11. ↑ Furie, Bruce; Bouchard, Beth A.; Furie, Barbara C. (1999). "Vitamin K-Dependent Biosynthesis of γ-Carboxyglutamic Acid". Blood. 93 (6): 1798–1808. doi:10.1182/blood.v93.6.1798.406k22_1798_1808. PMID   10068650 . Retrieved 2024-03-14.
  12. ↑ Tasheva M. (1995). "Anticoagulant rodenticides, evironmental health criteria 175" (PDF). World Health organization.
  13. ↑ Yu, C. C.; Atallah, Y. H.; Whitacre, D. M. (1982-11-01). "Metabolism and disposition of diphacinone in rats and mice". Drug Metabolism and Disposition. 10 (6): 645–648. ISSN   0090-9556. PMID   6130915.
  14. ↑ Whisson, Desley A.; Quinn, Jessica H.; Collins, Kellie; Engilis, Andrew (2004). "Developing a management strategy to reduce roof rat, Rattus rattus, impacts on open-cup nesting songbirds in California riparian forests". Proceedings of the Vertebrate Pest Conference. 21 (21). ISSN   0507-6773.
  15. ↑ Pitt, William C.; Driscoll, Laura C.; Sugihara, Robert T. (April 2011). "Efficacy of rodenticide baits for the control of three invasive rodent species in Hawaii". Archives of Environmental Contamination and Toxicology. 60 (3): 533–542. Bibcode:2011ArECT..60..533P. doi:10.1007/s00244-010-9554-x. ISSN   1432-0703. PMID   20552335.
  16. 1 2 3 Arjo, Wendy; Nolte, Dale (2004-05-09). "Assessing the efficacy of registered underground baiting products for mountain beaver (Aplodontia rufa) control". USDA Wildlife Services: Staff Publications. 23 (5): 425. Bibcode:2004CrPro..23..425A. doi:10.1016/j.cropro.2003.09.011.
  17. ↑ Pelfrene AF (2001). "Chlorophacinone - an overview | ScienceDirect Topics".
  18. ↑ Piero, Fabio Del; Poppenga, Robert H. (September 2006). "Chlorophacinone Exposure Causing an Epizootic of Acute Fatal Hemorrhage in Lambs". Journal of Veterinary Diagnostic Investigation. 18 (5): 483–485. doi:10.1177/104063870601800512. ISSN   1040-6387. PMID   17037620.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.